Eli Lilly and Company (NYSE:LLY) Price Target Cut to $1,015.00 by Analysts at Deutsche Bank Aktiengesellschaft

Eli Lilly and Company (NYSE:LLY) had its price objective decreased by stock analysts at Deutsche Bank Aktiengesellschaft from $1,025.00 to $1,015.00 in a research note issued to investors on Monday, Benzinga reports. The firm presently has a “buy” rating on the stock. Deutsche Bank Aktiengesellschaft’s price target points to a potential upside of 25.66% from the stock’s current price.

A number of other research firms have also issued reports on LLY. Bank of America cut their price target on shares of Eli Lilly and Company from $1,150.00 to $1,100.00 and set a “buy” rating on the stock in a report on Thursday. Barclays dropped their target price on Eli Lilly and Company from $1,025.00 to $975.00 and set an “overweight” rating for the company in a report on Thursday. BMO Capital Markets lifted their price target on Eli Lilly and Company from $1,001.00 to $1,101.00 and gave the company an “outperform” rating in a report on Friday, August 9th. Citigroup upped their target price on shares of Eli Lilly and Company from $1,060.00 to $1,250.00 and gave the company a “buy” rating in a research report on Friday, October 25th. Finally, Truist Financial lifted their price objective on Eli Lilly and Company from $1,000.00 to $1,033.00 and gave the company a “buy” rating in a report on Thursday, October 10th. Three analysts have rated the stock with a hold rating and sixteen have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $1,008.41.

Eli Lilly and Company Stock Down 1.4 %

NYSE LLY traded down $11.20 during trading hours on Monday, hitting $807.73. 2,313,484 shares of the company were exchanged, compared to its average volume of 3,052,141. The firm has a market cap of $766.79 billion, a price-to-earnings ratio of 87.32, a PEG ratio of 3.13 and a beta of 0.43. The company has a quick ratio of 0.87, a current ratio of 1.27 and a debt-to-equity ratio of 2.03. The company has a 50 day moving average of $911.04 and a two-hundred day moving average of $866.97. Eli Lilly and Company has a 52-week low of $561.65 and a 52-week high of $972.53.

Eli Lilly and Company (NYSE:LLY) last posted its earnings results on Wednesday, October 30th. The company reported $1.18 earnings per share for the quarter, missing the consensus estimate of $1.52 by ($0.34). The business had revenue of $11.44 billion for the quarter, compared to analysts’ expectations of $12.09 billion. Eli Lilly and Company had a net margin of 20.48% and a return on equity of 71.08%. The business’s revenue was up 20.4% compared to the same quarter last year. During the same quarter last year, the business posted $0.10 earnings per share. Equities research analysts anticipate that Eli Lilly and Company will post 13.23 earnings per share for the current year.

Institutional Trading of Eli Lilly and Company

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Tyler Stone Wealth Management increased its holdings in shares of Eli Lilly and Company by 258.3% in the third quarter. Tyler Stone Wealth Management now owns 1,125 shares of the company’s stock valued at $997,000 after purchasing an additional 811 shares during the period. Baker Avenue Asset Management LP lifted its stake in Eli Lilly and Company by 26.5% during the 3rd quarter. Baker Avenue Asset Management LP now owns 15,809 shares of the company’s stock valued at $14,006,000 after acquiring an additional 3,310 shares during the period. Colonial River Investments LLC boosted its holdings in shares of Eli Lilly and Company by 276.6% in the 3rd quarter. Colonial River Investments LLC now owns 2,011 shares of the company’s stock valued at $1,782,000 after acquiring an additional 1,477 shares during the last quarter. Mayflower Financial Advisors LLC increased its stake in shares of Eli Lilly and Company by 1.2% in the third quarter. Mayflower Financial Advisors LLC now owns 3,135 shares of the company’s stock worth $2,777,000 after acquiring an additional 37 shares during the period. Finally, Axxcess Wealth Management LLC raised its holdings in shares of Eli Lilly and Company by 4.2% during the third quarter. Axxcess Wealth Management LLC now owns 22,780 shares of the company’s stock worth $20,182,000 after purchasing an additional 916 shares during the last quarter. Institutional investors own 82.53% of the company’s stock.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.